Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > BUSINESS
BUSINESS
- DSP to Ship Almarl under New Brand Name from Mid-July
June 27, 2012
- Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey
June 27, 2012
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
- Otsuka, UCB Japan Apply for E Keppra for Pediatric Epilepsy
June 25, 2012
- GSK, DSP Launch Paxil CR Tablets
June 25, 2012
- Nexium Approved for Prevention of GU and DU in Patients Receiving Low-Dose Aspirin: Daiichi Sankyo, AZ
June 25, 2012
- Lyrica Approved for Pain Associated with Fibromyalgia: Pfizer Japan
June 25, 2012
- Two Generic Drug Makers Offer Different Views on Impact of Generic Name-based Prescriptions
June 22, 2012
- Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
June 22, 2012
- Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
June 21, 2012
- Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
June 21, 2012
- Teijin Pharma to Build New Laboratory to Support Increased Feburic Production and New Drug Development
June 21, 2012
- IBL, Trans Genic to Create Joint Venture for Diagnostic Agent Development and Clinical Tests
June 21, 2012
- Daiichi Sankyo to Market Ranbaxy Products in Venezuela
June 21, 2012
- Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review
June 20, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…